TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ____________________________________________________________________________ FORM 10-K Commission File Number 000-56607 BU ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-42140 Lakeside Holding Limited (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Revenue and Customer Base - Gentherm's revenues from its two largest customers, Lear Corporation and Adient plc, were $234 million and $164 million, representing 16% and 11% of total product revenues, respectively[46]. - In 2025, the top two customers, Lear and Adient, accounted for 16% and 11% of product revenues, respectively, while General Motors and Volkswagen each represented 12% of product revenues[63]. - Product revenues by OEM for 2025 show Volkswagen and General Motors at 12%, BMW at 9%, and Ford at 8%, reflecting a competitive landscape[47]. - In 2025, 66% of product revenue was generated from sales to customers outside the United States, including Europe and Asia[85]. - Over 15% of 2025 product revenue was generated from sales to customers in China, amid ongoing U.S.-China trade tensions[86]. Business Segments and Strategy - The company is organized into two reportable segments: Automotive and Medical, focusing on climate and comfort solutions in automotive and patient temperature management in the medical sector[18][19]. - Gentherm's automotive products include Climate Control Seats, Climate Control Interiors, and Lumbar and Massage Comfort Solutions, which are designed to enhance passenger comfort[14][27]. - Gentherm's strategy emphasizes profitable growth, operational excellence, and financial performance, leveraging core technologies to expand into new markets such as home and office, power-sports, and commercial vehicles[36][39]. - The automotive segment represents 97% of product revenues for the years ended December 31, 2025, 2024, and 2023, indicating a strong reliance on the automotive industry[73]. Financial Performance - For the year ended December 31, 2025, product revenues increased by 2.9% to $1,498,602 thousand compared to $1,456,124 thousand in 2024[191]. - Operating income for the year ended December 31, 2025, was $82,700 thousand, a decrease of $24,315 thousand from $107,015 thousand in 2024[191]. - The company reported a net income of $18,285 thousand for 2025, down from $64,947 thousand in 2024, reflecting a decline of $46,662 thousand[191]. - The cost of sales increased to $1,136,426 thousand in 2025 from $1,089,693 thousand in 2024, resulting in a gross margin decrease to $362,176 thousand[191]. - The company’s net research and development expenses rose to $94,759 thousand in 2025, compared to $88,697 thousand in 2024[191]. Operational Challenges - The company is subject to intense competition, particularly from Chinese-based component suppliers, which could impact pricing and margins[62]. - Seasonal fluctuations in automotive vehicle production are expected, particularly during summer and December, affecting operational performance[52]. - The global automotive supply chain has been adversely impacted by raw material shortages and manufacturing disruptions, which are expected to continue affecting profitability[77]. - The company’s ability to manage new product launches effectively is critical, as delays or quality issues could lead to significant financial penalties[70]. Research and Development - The company is committed to research and development, focusing on innovative products and partnerships to enhance energy utilization and production efficiencies[20][21]. - Gentherm's core technologies include thermal management, air moving devices, pneumatic solutions, and advanced valve systems, which are applicable across various end markets[22][23][25][26]. Mergers and Acquisitions - The company is pursuing a Reverse Morris Trust transaction with Modine Manufacturing Company, which involves the transfer of Modine's Performance Technologies business and the merger of SpinCo into Gentherm[16][17]. - The Modine Transaction is subject to conditions including shareholder approval and regulatory approvals, and failure to complete it could adversely impact the market price of the company's Common Stock[131]. - The integration of Performance Technologies following the Modine Transaction may present significant challenges, potentially affecting the combined company's business and financial condition[134]. Risks and Compliance - The company faces risks related to data privacy and security laws, which could lead to significant penalties and operational costs if not complied with[106]. - Regulatory changes, including tariffs and trade policies, could materially affect the company's operations and financial results, particularly in relation to supply chain costs and demand[104]. - The company is subject to extensive regulation in its patient temperature management business, with potential costs associated with compliance and inspections[116]. Capital Structure and Liquidity - As of December 31, 2025, the company's total consolidated indebtedness was $189.1 million, with $307.9 million available for additional borrowings under the Second Amended and Restated Credit Agreement[122]. - The company expects to incur significant one-time costs related to the Modine Transaction, which may include transaction-related fees and expenses, potentially impacting liquidity and cash flows[137]. - The company utilizes strategies to manage global liquidity needs, with $103.1 million in cash and cash equivalents held by non-U.S. subsidiaries as of December 31, 2025[126]. Shareholder Information - Current shareholders will experience substantial dilution in the Merger, with pre-Merger shareholders owning approximately 60% of the issued and outstanding shares of Common Stock on a fully diluted basis post-Merger[141]. - The company has not paid any cash dividends since formation and does not expect to pay any in the foreseeable future[161]. - The company authorized a stock repurchase program of up to $150.0 million over a three-year period, expiring June 30, 2027, with $10.0 million repurchased in 2025[162].

FNF Reports Fourth Quarter and Full Year 2025 Financial Results Jacksonville, Fla. – (February 19, 2026) - Fidelity National Financial, Inc. (NYSE:FNF) (FNF or the Company), a leading provider of title insurance and transaction services to the real estate and mortgage industries and a leading provider of insurance solutions serving retail annuity and life customers and institutional clients through its majority-owned, publicly traded subsidiary F&G Annuities & Life, Inc. (NYSE:FG) (F&G), today reported fina ...

Exhibit 99.1 RingCentral Announces Fourth Quarter and Fiscal Year 2025 Results Total revenue at $2.5 billion, up 5% Operating cash flow of $617 million, up 28% YoY; free cash flow of $530 million, up 32% YoY Initiates quarterly cash dividend of $0.075 per share Increases share repurchase authorization to $500 million "Our 2025 results reflect disciplined execution across growth, profitability, and capital allocation. We expanded GAAP operating margin to 4.8% and non-GAAP operating margin to 22.5%, generated ...

Hospital Operations - As of December 31, 2025, the company operated 104 critical illness recovery hospitals across 28 states, with approximately 37%, 33%, and 32% of revenue from Medicare reimbursement for the years ended December 31, 2023, 2024, and 2025, respectively [22]. - The company operated 1,917 outpatient rehabilitation clinics across 39 states and the District of Columbia as of December 31, 2025 [51]. - The company has a significant presence in the rehabilitation hospital segment, operating 38 rehabilitation hospitals in 15 states as of December 31, 2025 [63]. - As of December 31, 2025, the company operated 104 critical illness recovery hospitals and 38 rehabilitation hospitals, all certified by Medicare [100]. - The company operated 18 critical illness recovery hospitals and 11 rehabilitation hospitals that are treated as provider-based satellites, with 294 outpatient rehabilitation clinics also classified as provider-based [163]. Patient Care and Quality - The average length of stay for patients in critical illness recovery hospitals was 31 days for the year ended December 31, 2025 [24]. - The average length of stay for patients in rehabilitation hospitals was 14 days for the year ended December 31, 2025 [38]. - All rehabilitation hospitals were accredited by TJC and certified by Medicare as inpatient rehabilitation facilities as of December 31, 2025 [39]. - The company focuses on high-quality care and service, utilizing patient satisfaction surveys to continuously improve service levels [55]. - The company maintains quality assurance programs to support and monitor care standards, ensuring compliance with regulatory requirements and Medicare certifications [31]. Financial Performance - Medicare accounted for 28.6% of the company's revenue in 2025, while commercial insurance represented 51.6% [71]. - Revenue from workers' compensation programs accounted for approximately 15% of outpatient rehabilitation segment revenue, 2% of rehabilitation hospital segment revenue, and 1% of critical illness recovery hospital segment revenue for the year ended December 31, 2025 [102]. - The company's revenue sources include Medicare and Medicaid, which generally pay less than customary charges for services provided [73]. - The company employed approximately 45,300 employees, including 30,800 full-time and 14,500 part-time employees [75]. - The company has approximately 17,500 credentialed practitioners providing services in its hospitals [78]. Strategic Growth - The company is pursuing opportunistic acquisitions to grow its network of critical illness recovery hospitals, focusing on improving financial performance through clinical program additions and centralized administrative functions [36]. - The company aims to increase commercial volume by expanding relationships with commercial insurers, offering high-quality, cost-effective care [35]. - The company aims to increase market share by opening new clinics in existing markets and entering joint ventures with hospital systems [56]. - The company is pursuing opportunistic acquisitions to grow its network of rehabilitation facilities and improve financial performance [60]. Regulatory Compliance - The company is required to comply with the Health Insurance Portability and Accountability Act (HIPAA) and has a Privacy and Security Committee to monitor compliance, which has not materially affected its financial condition [169]. - The company must provide clear pricing information online for at least 300 "shoppable services" as mandated by new regulations effective January 1, 2021 [174]. - The Stark Law imposes penalties for prohibited referrals, including civil monetary penalties of up to $15,000 per service and exclusion from federal healthcare programs [162]. - The company is required to monitor government publications to enhance compliance efforts related to fraud and abuse enforcement [159]. - The Compliance and Audit Committee meets quarterly to review compliance program activities and ensure adherence to regulatory requirements [182]. Operational Challenges - The company faces significant operating issues due to shortages of clinical personnel, which may lead to increased use of costly temporary labor [76]. - The company has implemented a communications tool called the "10-Foot Circle of Employee Safety," resulting in significant reductions in workplace injuries [87]. - The company maintains strong community and employee relations, emphasizing quality care and customer service to drive patient volume [59]. Financial Obligations - As of December 31, 2025, Select had outstanding borrowings of $1,039.5 million under a term loan and $100.0 million under a revolving facility, with variable interest rates [444]. - An interest rate cap was entered into on March 31, 2025, limiting the Term SOFR rate to 4.5% on $1.0 billion of principal outstanding under the term loan, applicable through March 31, 2028 [445]. - A 0.25% increase in market interest rates will impact the annual interest expense on variable rate debt by $2.8 million per year [446].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K ____________________________________ ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36257 TRAVERE THERAPEUTICS, INC. (Exact Name of Registrant as specified in its Charter) Delaware 27-484269 ...

Exhibit 99.1 Century Aluminum Company Reports Fourth Quarter 2025 Results Chicago, February 19, 2026 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ: CENX) today announced its fourth quarter and full year 2025 results. Fourth Quarter 2025 Highlights Full Year 2025 Highlights Fourth Quarter & Full Year 2025 Financial Results | $MM (except shipments and per share data) | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | | | Q4 2025 | Q3 2025 | | FY 2025 | FY 2024 | | Shipments (tonnes) | | 140,25 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-09447 KAISER ALUMINUM CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3030279 (State or other jurisdiction of incorpo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32601 LIVE NATION ENTERTAINMENT, INC. (Exact name of registrant as specified in its charter) Delawar ...